News | April 01, 2022
Oragnon enters global licencing agreement with Dare Biosciences
An estimated 21 million American women experience BV
An estimated 21 million American women experience BV
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Subscribe To Our Newsletter & Stay Updated
